Popular search terms:
Search Results
122 results found-
Our Products | CSL Behring Australia
CSL Behring provides protein-based therapies for bleeding disorders, critical care, pulmonary disease, and other rare illnesses.
https://www.cslbehring.com.au/products -
Products List | CSL Behring Australia
CSL Behring Australia's Product Information (PI), Consumer Medicine Information (CMI), Safety Data Sheets and New Zealand Data Sheet
https://www.cslbehring.com.au/products/products-list -
Australian PI . Hizentra
Patients with anti-IgA antibodies, in whom treatment with subcutaneous IgG products remains the only option, should be switched to Hizentra® only under close medical supervision.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/hizentra-product-information-1200.pdf -
Biostate Data Sheet
In general, all patients treated with coagulation FVIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/biostate-nz-ds1900.pdf -
RiaSTAP AU PI
Resulting from these studies, as well as from long lasting clinical experience with fibrinogen products, dosage recommendations in the treatment of children are the same as for adults.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/riastap-au-pi-v1000.pdf -
Product Orders | CSL Behring Australia
CSL Behring Online Order & Receipt System
https://www.cslbehring.com.au/product-orders -
Hizentra Data Sheet
Patients with anti-IgA antibodies, in whom treatment with subcutaneous IgG products remains the only option, should be switched to Hizentra® only under close medical supervision.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/hizentra-nz-ds-800.pdf -
Riastap Data Sheet
Resulting from these studies, as well as from long lasting clinical experience with fibrinogen products, dosage recommendations in the treatment of children are the same as for adults.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/riastap-nz-ds-v1000-with-wfi.pdf -
Australian PI . tradename (active ingredient)
The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain infectious agents and by testing for the presence of certain viral markers.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/thrombotrolvf-au-pi-1000.pdf -
Australian PI . Rhophylac
Treatment of Rh(D)-negative persons after incompatible transfusions of Rh(D)-positive blood or other products containing red blood cells.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/rhophylac-product-information-700.pdf